'Game-Changer' Drug?

Arteriosclerosis (or Atherosclerosis) is a condition where blood vessels become semi-blocked by plaque. Build-up of plaque, greatly increases the risk of blood clots causing heart attacks or strokes (the vessels supplying blood to the heart and the brain are relatively narrow). Plaque is largely produced by Low Density Lipoprotein (LDL), sometimes known as 'bad cholesterol'. There are two potential sources of LDL. Ingested in a diet rich in saturated fats and/or manufactured by one's own liver. Obviously, one can change the diet but, until now, statins have been the only treatment for reducing LDL levels. Statins don't, however, suit everyone. It has now been announced that the UK's National Institute for Health and Care Excellence (NICE) will approve a Novartis drug, Inclisiran, for use in England (https://www.theguardian.com/science/2021/sep/01/gamechanging-heart-disease-drug-approved-for-use-in-england). NICE judge medical drugs and treatments, using a costs versus benefits calculation. They have approved Inclisiran after Novartis offered a discount on the price of the drug. Inclisaran is given as two injections per year and acts on the liver, reducing LDLs. The treatment can be given with or without statins. Inclisaran will be offered to patients with primary Hypercholestolaemia (whose livers produce too much LDL) or mixed Dyslipidaemia (with high liver LDL and low titres of 'good cholesterol' or HDL). This drug will save thousands of lives each year in England. Inclisaran will also reduce the costs to the National Health Service, of treating people (usually men), who have experienced heart attacks or strokes.